PCI Pharma Services News and Resources

PCI Pharma Services has announced its acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and subsidiary of Ajinomoto Co., Inc. The transaction, set to finalise in May 2025, marks a strategic move by PCI to enhance its global presence and

PCI Pharma Services has announced a successful collaboration with ChiRhoClin, Inc., a theranostics specialist, to prevent a potential shortage of ChiRhoStim (Human Secretin for Injection), a critical diagnostic drug used for testing pancreatic diseases and cancer. The partnership aims to

PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced plans to invest over $365 million in new and expanded facilities to support the packaging of drug-device combination products. The expansion focuses on advanced drug delivery systems,

PCI Pharma Services has become the first contract development and manufacturing organization (CDMO) to successfully navigate the International Coalition of Medicines Regulatory Authorities (ICMRA) inspection process under its new Collaborative Hybrid Inspection Pilot (CHIP) program. The inspection took place at

PCI Pharma Services, a pharmaceutical CDMO, has announced a 25-year lease agreement to construct a new industrial facility at CityNorth Business Campus in Stamullen, Co. Meath, Ireland. This development, strategically located with direct access to the M1 motorway, will bolster

PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has initiated the installation of crucial equipment for its latest sterile fill-finish facility at its Bedford, New Hampshire campus. This development is part of a multi-year $100 million investment